Comparison of the Development of CDMO at Home and Abroad and Its Enlightment to China

Abstract

Objective To analyze the development status of contract development manufacturing organization (CDMO) at home and abroad, and to make some suggestions for the development of CDMO in China. Methods The relevant literature was searched and reviewed, and the development status of CDMOs in the United States, France, Japan and China was compared from the aspects of market scale, development process, development focus, advantages and disadvantages, and policy support. Then, some suggestions for the development of CDMO enterprises in China were summarized. Results and Conclusion Through the comparison of CDMO development at home and abroad, it can be seen that China started CDMO late, there were many technical barriers and its globalization layout were not sufficient. However, the development trend was good and it focused on the field of chemical drugs and biological drugs to constantly develop innovative drugs. China needs to continuously improve its own technical capabilities to carry out innovative research. Therefore, cost reduction and efficiency increase will be the key elements for the development of CDMOs, and they are expected to have a rapid and comprehensive development in the future.

Keywords

CDMO / current situation of enterprise development / domestic and international comparison / policy implications

References

[1] Mao kaiyun, Zhao Ruochun, Wang Yue, et al. Analysis on the development trend of CMO/CDMOS industry in global cell therapy[J]. Chinese Journal of Biological Engineering, 2020, 40 (6): 106-112.

[2] Zhang Yixin. CDMO is in full swing! From “speed comparison” to “high-end competition”[N]. Medicine Economic News, 2018-03-29 (008).

[3] Zhang Lixin, Wu Sizhu, Tang Mingkun, et al. The federal data strategy and 2020 action plan and their governing logic and enlightenments[J]. Chinese Journal of Medical Library and Information Science, 2021, 30 (2): 13-19.

[4] Cao Feng. Outlook and investment strategy analysis of Chinese biopharmaceutical CDMO/CMO[J]. Zhangjiang Technology Review, 2019 (5): 56-57.

[5] Sullivan. Current perspective and future development on CDMO market report[R]. 2022.

[6] Wu Yixuan, Wu Jixia. Many pharmaceutical companies expand CDMO business industry competition is becoming more and more fierce[N]. Securities Daily, 2022-11-16 (B2).

[7] Wei Wanyi. CDMO enterprise equity incentive scheme design and company performance - take Wuxi App Tech as an example[D]. Gansu University of Political Science and Law, 2022.